Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17 beta-estradiol and norethisterone acetate
(2002) In Menopause 9(5). p.335-342- Abstract
- Objective: To evaluate the modification of lipid and lipoprotein by use of low doses of continuous-combined formulations of 17beta-estradiol (E-2) and norethisterone acetate (NETA) in healthy postmenopausal women. Design: The study was designed as a double-blind, randomized, placebo-controlled trial. A total of 120 healthy postmenopausal women were randomized to one of three treatment arms: (1) placebo group (n = 40); (2) E-2/NETA 0.25-mg group-subjects receiving oral continuous-combined E-2 1 mg and NETA 0.25 mg (n = 40); (3) E2/NETA 0.5-mg group-women who were treated with E-2 1 mg and NETA 0.5 mg (n = 40). The duration of study was 12 months. Plasma levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein... (More)
- Objective: To evaluate the modification of lipid and lipoprotein by use of low doses of continuous-combined formulations of 17beta-estradiol (E-2) and norethisterone acetate (NETA) in healthy postmenopausal women. Design: The study was designed as a double-blind, randomized, placebo-controlled trial. A total of 120 healthy postmenopausal women were randomized to one of three treatment arms: (1) placebo group (n = 40); (2) E-2/NETA 0.25-mg group-subjects receiving oral continuous-combined E-2 1 mg and NETA 0.25 mg (n = 40); (3) E2/NETA 0.5-mg group-women who were treated with E-2 1 mg and NETA 0.5 mg (n = 40). The duration of study was 12 months. Plasma levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very low-density lipoprotein (VLDL) cholesterol, triglycerides, lipoprotein(a), apolipoprotein A and apolipoprotein B were determined on four occasions (i.e., baseline, 3-, 6-, and 12-month visits). Results: There were no differences in the baseline characteristics among the three groups. A total of 102 women completed the study, resulting in a compliance rate of 85%. There was a significant reduction of total cholesterol, LDL cholesterol, and lipoprotein(a) in both combined groups when compared with placebo. The level of apolipoprotein B declined significantly only in the E-2/NETA 0.25-mg group. Decrements were observed within 3 months of treatment and maintained thereafter. No significant changes were found in triglycerides, VLDL cholesterol, HDL cholesterol, apolipoprotein A, and LDL/HDL ratio. Between the two active combined groups, no statistically significant differences were noted. Conclusion: Favorable changes in lipids and lipoproteins were associated with the low dose of E-2/NETA combinations. These effects may contribute to the reduction or prevention of atherogenesis in postmenopausal women. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/329082
- author
- Samsioe, Göran LU ; Li, Cairu LU ; Borgfeldt, Christer LU ; Wilawan, K ; Åberg, Anders E LU and Larsen, S
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- replacement therapy, hormone, lipoprotein, lipid, estradiol, norethisterone acetate
- in
- Menopause
- volume
- 9
- issue
- 5
- pages
- 335 - 342
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000177857200006
- ISSN
- 1530-0374
- DOI
- 10.1097/01.GME.0000019564.35939.F8
- language
- English
- LU publication?
- yes
- id
- d2947f44-dfb5-4a12-914b-fc2ae6c9f261 (old id 329082)
- date added to LUP
- 2016-04-01 12:03:00
- date last changed
- 2018-11-21 20:03:13
@article{d2947f44-dfb5-4a12-914b-fc2ae6c9f261,
abstract = {{Objective: To evaluate the modification of lipid and lipoprotein by use of low doses of continuous-combined formulations of 17beta-estradiol (E-2) and norethisterone acetate (NETA) in healthy postmenopausal women. Design: The study was designed as a double-blind, randomized, placebo-controlled trial. A total of 120 healthy postmenopausal women were randomized to one of three treatment arms: (1) placebo group (n = 40); (2) E-2/NETA 0.25-mg group-subjects receiving oral continuous-combined E-2 1 mg and NETA 0.25 mg (n = 40); (3) E2/NETA 0.5-mg group-women who were treated with E-2 1 mg and NETA 0.5 mg (n = 40). The duration of study was 12 months. Plasma levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very low-density lipoprotein (VLDL) cholesterol, triglycerides, lipoprotein(a), apolipoprotein A and apolipoprotein B were determined on four occasions (i.e., baseline, 3-, 6-, and 12-month visits). Results: There were no differences in the baseline characteristics among the three groups. A total of 102 women completed the study, resulting in a compliance rate of 85%. There was a significant reduction of total cholesterol, LDL cholesterol, and lipoprotein(a) in both combined groups when compared with placebo. The level of apolipoprotein B declined significantly only in the E-2/NETA 0.25-mg group. Decrements were observed within 3 months of treatment and maintained thereafter. No significant changes were found in triglycerides, VLDL cholesterol, HDL cholesterol, apolipoprotein A, and LDL/HDL ratio. Between the two active combined groups, no statistically significant differences were noted. Conclusion: Favorable changes in lipids and lipoproteins were associated with the low dose of E-2/NETA combinations. These effects may contribute to the reduction or prevention of atherogenesis in postmenopausal women.}},
author = {{Samsioe, Göran and Li, Cairu and Borgfeldt, Christer and Wilawan, K and Åberg, Anders E and Larsen, S}},
issn = {{1530-0374}},
keywords = {{replacement therapy; hormone; lipoprotein; lipid; estradiol; norethisterone acetate}},
language = {{eng}},
number = {{5}},
pages = {{335--342}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Menopause}},
title = {{Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17 beta-estradiol and norethisterone acetate}},
url = {{http://dx.doi.org/10.1097/01.GME.0000019564.35939.F8}},
doi = {{10.1097/01.GME.0000019564.35939.F8}},
volume = {{9}},
year = {{2002}},
}